Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities

NCT05808322 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Ropeginterferon alfa-2b
PROCEDURE: SOC

Sponsor

National Taiwan University Hospital